{"entity":{"id":"nct04597671","kind":"trial","name":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)","aka":["NVALT28"],"tldr":"A phase 3 trial of durvalumab in lung cancer, run by Association NVALT Studies, active but no longer recruiting.","summary":"Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28) is a phase 3, randomised interventional study registered as NCT04597671 by Association NVALT Studies, with a registry enrolment figure of 170 participants, started 2021-12-06 and due to reach its primary completion in 2028-12. Interventions recorded: Durvalumab; low-dose PCI. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Reduction of incidence of brain metastases. Lung eligibility wording from the registry: \"TNM8 stage IIIA, IIIB or IIIC non-small cell lung cancer before start of concurrent chemoradiotherapy (preferentially histology; cytology is allowed)\". Sites: Netherlands. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04597671","url":"https://clinicaltrials.gov/study/NCT04597671"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["stage-iii-unresectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["durvalumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04597671","phase":"3","setting":"NVALT 28/ PRL01 Durvalumab and Low-dose Prophylactic Cranial Irradiation (PCI) Versus Durvalumab and Observation in Radically Treated Patients With Stage III Non-small Cell Lung Cancer: A Phase III Randomized Study","sponsor":"Association NVALT Studies","enrolled":170,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04597671/","neighbours":{"cancer":[{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}